drugset / Trial / NCT04226365

Pediatric Concussion Outcomes

NCT04226365

Phase 4 Terminated 8 enrolled Lancaster General Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a randomized, placebo-controlled, double-blinded trial in which subjects with a post concussive headache meeting inclusion criterion will be assigned to one of two treatment groups: placebo or nortriptyline. Each group will be evaluated at week 0 and again each week for the next 4 weeks of treatment with a concussion survey that rates their symptoms. At the end of 4 weeks the study will be unblinded. It is hypothesized that the addition of nortriptyline to the standard headache treatments will result in more rapid decrease of symptom score than with placebo.

Timeline

Start
2020-02-15
Primary completion
2023-05-31
Completion
2023-05-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Nortriptyline Small molecule 10 mg Oral